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PreviewsThis exciting study from Wang and
colleagues has provided us with insight
into the formation of the H3K27me3
mark at developmentally regulated genes.
Of particular note, Msx1 is expressed in
cells of the developing limb bud that
have not yet committed to the skeletal
muscle lineage. As H3K27me3 enrich-
ment at the nuclear periphery has previ-
ously been observed in ES cells, it will
be of interest to determine whether the
remarkable spatial reorganization of this
transcriptionally repressive mark is also
present in other multi-potent cell types.392 Developmental Cell 21, September 13, 20REFERENCES
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Continuous developmental maturation of cardiomyocytes is essential to meet the functional and metabolic
demands of the growing heart. A new study (Hom et al., 2011) reports that embryonic cardiomyocytes are
influenced by mitochondrial maturation, such that closure of the mitochondrial permeability transition pore
results in decreased levels of reactive oxygen species, thereby inducing differentiation.Unraveling the molecular program that
induces and establishes differentiation
and maturation of cardiomyocytes during
heart development is imperative for un-
derstanding the pathogenesis of pre-
and postnatal cardiac disease as well as
for therapeutic approaches aiming for
regeneration of damaged myocardium.
Although a multitude of transcription
factors and small molecules have been
identified that promote or inhibit cardio-
myogenesis, their precise interaction is
incompletely understood. This is compli-
cated by the fact that cardiomyocyte
differentiation is not only reflected by the
assembly of a contractile apparatus but
involves changes in cellular metabolism,
cell-cell communication, and organelle
structure. In this issue of Developmental
Cell, Hom et al. (2011) add another level
of complexity by reporting that cardio-
myocyte differentiation in the embryonic
heart is directly controlled by mitochon-drial maturation. The authors show that
mouse hearts at embryonic day (E) 9.5
contain relatively few and immature mito-
chondria, characterized by rare and disor-
ganized cristae. In E13.5 hearts, in con-
trast, the mitochondrial mass increases
substantially, accompanied by matura-
tion of the organelle as indicated by abun-
dant laminar cristae.
While these findings per se might be
regarded as a consequence (rather than
a cause) of cardiomyocyte differentiation
and could just reflect the increasing con-
tractile and therefore metabolic demands
of the developing heart, the authors
instead demonstrate that mitochondrial
maturation induces cardiomyocyte differ-
entiation. In vitro studies revealed that
cardiomyocytes from E9.5 hearts exhibit
a reduced mitochondrial membrane
potential as well as increased levels of
reactiveoxygen species (ROS)whencom-
pared to E13.5 cardiomyocytes. Thesefindings are characteristic for opening of
the mitochondrial permeability transition
pore (mPTP)within the innermitochondrial
membrane and suggest that the mPTP is
open in early embryonic cardiomyocytes
but closes upon developmental progres-
sion. Indeed, the authors could show that
closing the mPTP in E9.5 cardiomyocytes
by pharmacological or genetic manipula-
tions results in functional as well as
morphological maturation of mitochon-
dria. Importantly, closing the mPTP
induces differentiation of early (but not
late) cardiomyocytes, which is evident as
an increase in the number of sarcomeres
per cell. This effect is dependent on intra-
cellular ROS levels, which are high in
E9.5 cardiomyocytes but drop upon
physiological as well as induced closure
of the mPTP. The authors could show
that pharmacologically reducing ROS
levels in early cardiomyocytes mimics
the effect of mPTP closure and promotes
Developmental Cell
Previewsdifferentiation; conversely, maintaining
highly oxidative conditions prevents
differentiation.
An intriguing question arising from
these studies concerns the characteriza-
tion of the redox signaling pathways that
mediate cardiomyocyte differentiation
downstream of changes in ROS levels.
ROS have long been identified as impor-
tant modulators of intracellular signaling
events in the adult heart impacting on car-
diomyocyte growth and stress response
(Sugden and Clerk, 2006). Additionally,
ROS have been shown to promote
the differentiation of embryonic stem
(ES) cells into cardiomyocytes in vitro,
although it has been proposed that this
might be dependent on ROS levels: low
concentrations of H2O2 promote while
high concentrations inhibit cardiomyo-
genesis (Puceat, 2005). This aside, ROS
have been shown to induce the expres-
sion of various cardiac-specific genes
and transcription factors such as Gata4,
Nkx2.5, and Mef2c in ES cells (Buggisch
et al., 2007). In contrast, cardiac gene
expression was inhibited in neonatal rat
cardiomyocytes treated with H2O2 (Torti
et al., 1998). The present study by Hom
et al. (2011) might shed some light on
the complex role of redox signaling during
cardiomyogenesis such that the effect of
ROS might be both stage- and dose-
dependent: while in the early embryo the
initial commitment of cardiac progenitor
cells toward the cardiac lineage could be
promoted by ROS, further differentiation
into mature cardiomyocytes seems to
require a drop in intracellular ROS levels.
Whether the changes in the oxidative
environment between the E9.5 and
E13.5 heart are converted into a transcrip-
tional response by increasing the expres-
sion of cardiomyocyte-specific genes or
whether they directly impact on sarco-
mere assembly and function by altering
the oxidative state of sarcomere proteins
(Sumandea and Steinberg, 2011) will
have to be determined.
Another interesting perspective derived
from the study of Hom et al. (2011) relates
to the mechanisms that mediate mPTP
closure during heart development. Given
that preventing mPTP opening seems to
be important for ischemic preconditioning
(IPC) in the heart, thereby reducing is-
chemia reperfusion injury, understanding
closure of the mPTP during heart devel-opment might identify new mechanisms
of cardioprotection. In this regard it has
been proposed that IPC-induced inhibi-
tion ofmPTP opening is partially mediated
by reduced oxidative stress during is-
chemia and reperfusion (Clarke et al.,
2008). Whether this reflects reduced
production or increased removal of ROS
in preconditioned hearts has not been
firmly established. In the context of the
embryonic heart, given that the balance
between oxidative stress and antioxida-
tive enzymes is critical for embryogenesis
(Dennery, 2007), establishing a functional
intracellular antioxidative defense be-
tween E9.5 and E13.5 might result in
reduced ROS levels which in turn lead to
closure of the mPTP thereby further
decreasing ROS production and inducing
cardiomyocyte differentiation.
On the other hand, epigenetic factors
such as changes in intracardiac hemody-
namics or mechanical stress between
E9.5 and E13.5 could induce mitochon-
drial maturation and mPTP closure. In
this regard it is worth noting that stretch
stimulates ES cell differentiation into
cardiomyocytes and this response is
dependent on increased ROS production
(Schmelter et al., 2006). The morpholog-
ical changes occurring between E9.5
and E13.5 in the heart coincidewith signif-
icant changes in mechanical load, con-
tractile force generation, and blood flow,
which therefore could impact on mito-
chondrial maturation and consequently
cardiomyocyte differentiation. Intrigu-
ingly, the degree of cardiomyocyte differ-
entiation is not uniform within the embry-
onic heart, but cells in the outer compact
layer are less differentiated compared to
cells in the trabeculated myocardium.
This could implicate a differential regula-
tion of mPTP activity across the ventric-
ular wall with a closed mPTP in trabecu-
lated myocardium but a more open state
in the compact layer. At the same time,
compact myocardium shows a much
higher proliferation rate during heart
development than trabeculated myocar-
dium, suggesting that mitochondrial mat-
uration and mPTP closure might directly
or indirectly impact on cardiomyocyte
cell-cycle regulation. Therefore, by influ-
encing both cardiomyocyte differentiation
and proliferation, manipulating the mPTP
would be an attractive target for regener-
ative therapies in the heart. Indeed, treat-Developmental Cell 21, Seing early cardiac progenitor cells with the
mPTP inhibitor cyclosporin A dramatically
increased the yield of beating cardiomyo-
cytes, which were also shown to integrate
into infarcted myocardium (Yan et al.,
2009).
Finally, the opening of the mPTP and
the resulting decrease in mitochondrial
membrane potential as well as release of
mitochondrial proteins into the cytoplasm
are widely recognized as key steps
toward cardiomyocyte death. Therefore,
the fact that cell death is prevented in
E9.5 hearts despite opening of the
mPTP suggests the presence of specific
cell survival mechanisms in early embry-
onic cardiomyocytes that might be lost
later during development.
In summary, the findings by Hom et al.
(2011) have not only added an important
aspect to understanding heart devel-
opment and cardiomyocyte differentia-
tion but the further characterization of
the underlying molecular mechanisms
might also provide new insights into
both cardioprotection and myocardial
regeneration.REFERENCES
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